ESR1 and breast carcinoma: Increased expression of co-activator proteins that mediate ER activity or downregulation of co-repressor activity reducing the inhibitory potential of tamoxifen are possible molecular mechanisms for resistance and the progression of confined breast cancer to invasive disease (7–9).